Table 2 Patients and the tumor characteristics of CRC adenocarcinoma in FFPE, fresh tissue and plasma studies. *N/A: Not applicable.
Type | Biological FFPE tissue validation | Biological fresh tissue validation | Tissue expression | Plasma study | ||||
|---|---|---|---|---|---|---|---|---|
Cases | Control | Cases | Control | Cases | Control | Cases | Control | |
Number | (N = 39) | (N = 47) | (N = 28) | (N = 26) | (N = 33) | (N = 35) | (N = 22) | (N = 20) |
Gender | ||||||||
Male | 23 (59%) | 27 (57%) | 19 (68%) | 18 (69) | 19 (57%) | 17 (48%) | 13 (59%) | 11(55%) |
Female | 16 (41%) | 20 (43%) | 9 (32%) | 8 (31) | 14 (43) | 18 (52%) | 9 (41%) | 9 (45%) |
Age at Diagnosis (Year) | ||||||||
Median | 58 | 61 | 67 | 59 | 59 | 56 | 67 | 56 |
Range | [24–85] | [24–85] | [44–82] | [45–84] | [24–85] | [35–77] | [44–82] | [45–84] |
Tumor site | ||||||||
Anal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
Rectum | 3 (8%) | 4 (8%) | 10 (36%) | 9 (35%) | 2 (6%) | 0 | 8 (36%) | — |
Sigmoid | 20(51%) | 24 (51%) | 6 (21%) | 12 (46%) | 18 (54%) | 21 (60%) | 4 (18%) | — |
Transverse colon | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
Descending colon | 4 (10%) | 5 (11%) | 1 (3%) | 0 | 3 (9%) | 7 (20%) | 1 (5%) | — |
Ascending colon | 7 (18%) | 7 (15%) | 3 (11%) | 1 (4%) | 5 (15%) | 0 | 3 (14%) | — |
Cecum | 2 (5%) | 2 (4%) | 8 (29%) | 4 (15%) | 2 (6%) | 0 | 6 (27%) | — |
Entire colon | 3 (8%) | 5 (11%) | 0 | 0 | 3 (9%) | 7 (20%) | 0 | — |
TNM stage | ||||||||
I | 7 (18%) | — | N/A | — | 6 (18%) | — | N/A | — |
IIA | 8 (21%) | — | N/A | — | 6 (18%) | — | N/A | — |
IIB | 2 (5%) | — | N/A | — | 2 (6%) | — | N/A | — |
IIC | 1 (2%) | — | N/A | — | 1 (3%) | — | N/A | — |
IIIA | 2 (5%) | — | N/A | — | 2 (6%) | — | N/A | — |
IIIB | 10 (26%) | — | N/A | — | 7 (21%) | — | N/A | — |
IIIC | 9 (23%) | — | N/A | — | 9 (27%) | — | N/A | — |
IVA | 0 | — | N/A | — | 0 | — | N/A | — |
IVB | 0 | — | N/A | — | 0 | — | N/A | — |
Tumor size | ||||||||
≥4 | 15 (39%) | — | N/A | — | 10 (30%) | — | N/A | — |
4.1–7.9 | 20 (51%) | — | N/A | — | 20 (61%) | — | N/A | — |
8–11.9 | 2 (5%) | — | N/A | — | 1 (3%) | — | N/A | — |
≤12 cm | 2 (5%) | — | N/A | — | 2 (6%) | — | N/A | — |
Mean of Cq | 29.7 | 35.5 | 29.7 | 35 | 32.5 | 27.8 | 36.3 | 0 |
KRAS mutation | 19 (49%) | — | 9 (32%) | — | 12 (36%) | — | 6 (27%) | — |
BRAF mutation | 9 (23%) | — | 3 (11%) | — | 5 (15%) | — | 2 (9%) | — |
Diagnostic | ||||||||
Sensitivity | 87% | 82% | — | 41% | ||||
Specificity | 100% | 92% | — | 100% | ||||
